Charlott Mörth

Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study

Sabaa, Amal Abu; Mörth, Charlott; Hasselblom, Sverker; Hedström, Gustaf et al.

Part of British Journal of Haematology, p. 906-914, 2021

• DOI for Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study
• Download full text (pdf) of Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study

Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma

Mörth, Charlott; Sabaa, Amal Abu; Freyhult, Eva; Christersson, Christina et al.

Part of Cardio-Oncology, 2021

• DOI for Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma
• Download full text (pdf) of Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma

Clinical and tumour biology studies of Diffuse Large B-cell Lymphoma: with emphasis on comorbidity, toxicity and outcome

Mörth, Charlott

2020

• Download full text (pdf) of Clinical and tumour biology studies of Diffuse Large B-cell Lymphoma: with emphasis on comorbidity, toxicity and outcome

Autoimmune disease in patients with diffuse large B-cell lymphoma: occurrence and impact on outcome

Mörth, Charlott; Valachis, Antonios; Sabaa, Amal Abu; Marshall, Katharina et al.

Part of Acta Oncologica, p. 1170-1177, 2019

• DOI for Autoimmune disease in patients with diffuse large B-cell lymphoma: occurrence and impact on outcome

Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?

Mörth, Charlott; Valachis, Antonis; Sabaa, Amal Abu; Molin, Daniel et al.

Part of Annals of Hematology, p. 2129-2135, 2018

• DOI for Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?
• Download full text (pdf) of Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?

Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study

Sabaa, Amal Abu; Mörth, Charlott; Hasselblom, Sverker; Hedström, Gustaf et al.

Part of British Journal of Haematology, p. 906-914, 2021

• DOI for Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study
• Download full text (pdf) of Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study

Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma

Mörth, Charlott; Sabaa, Amal Abu; Freyhult, Eva; Christersson, Christina et al.

Part of Cardio-Oncology, 2021

• DOI for Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma
• Download full text (pdf) of Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma

Autoimmune disease in patients with diffuse large B-cell lymphoma: occurrence and impact on outcome

Mörth, Charlott; Valachis, Antonios; Sabaa, Amal Abu; Marshall, Katharina et al.

Part of Acta Oncologica, p. 1170-1177, 2019

• DOI for Autoimmune disease in patients with diffuse large B-cell lymphoma: occurrence and impact on outcome

Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?

Mörth, Charlott; Valachis, Antonis; Sabaa, Amal Abu; Molin, Daniel et al.

Part of Annals of Hematology, p. 2129-2135, 2018

• DOI for Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?
• Download full text (pdf) of Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?

Does the omission of vincristine affect outcome and survival in patients with diffuse large B-cell lymphoma?

Mörth, Charlott; Valachis, Antonis; Abu Sabaa, Amal; Hedström, Gustaf et al.

Part of Annals of Oncology, 2017

Validation and optimization of a predictive model for radiation pneumonitis in patients with lung cancer

Mörth, Charlott; Kafantaris, Ioannis; Castegren, Markus; Valachis, Antonios

Part of Oncology Letters, p. 1144-1148, 2016

• DOI for Validation and optimization of a predictive model for radiation pneumonitis in patients with lung cancer

Single-agent versus combination chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer and performance status 2: A literature-based meta-analysis of randomized studies

Mörth, Charlott; Valachis, Antonis

Part of Lung Cancer, p. 209-214, 2014

• DOI for Single-agent versus combination chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer and performance status 2: A literature-based meta-analysis of randomized studies

Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving EFS24 - a Swedish population-based study.

Sabaa, Amal Abu; Mörth, Charlott; Hasselblom, Sverker; Hedström, Gustaf et al.

Clinical and tumour biology studies of Diffuse Large B-cell Lymphoma: with emphasis on comorbidity, toxicity and outcome

Mörth, Charlott

2020

• Download full text (pdf) of Clinical and tumour biology studies of Diffuse Large B-cell Lymphoma: with emphasis on comorbidity, toxicity and outcome

T-cell Leukaemia/Lymphoma Protein 1A (TCL1A) In Diffuse Large B-cell lymphoma (DLBCL)

Abu Sabaa, Amal; Mörth, Charlott; Berglund, Mattias; Hashemi, Jamileh et al.

Plasma Protein Profiling using Multiplex Extension Assay in Diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP: A descriptive study

Abu Sabaa, Amal; Mörth, Charlott; Molin, Daniel; Freyhult, Eva et al.